自和抗炎症改善糖尿病神经病变与Rilmenidine
Mehmet Burak Yalçın1, Ejder Saylav Bora2, Adem Çakır3
1Bahcelievler Memorial Hospital - Department of Orthopedics and Traumatology - Istanbul - Turkey.
Acta cirurgica brasileira
|December 6, 2023
概括
里尔梅尼丁治疗减少了糖尿病大鼠的炎症和纤维化,改善了神经功能和抗氧化能力. 这表明里尔梅尼丁可能是糖尿病外围神经病变 (DPN) 的潜在治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 糖尿病外围神经病变 (DPN) 是糖尿病的一个常见并发症.
- DPN的特点是神经损伤,炎症和神经功能受损.
- 目前对DPN的治疗方法有限,专注于症状管理.
研究的目的:
- 在大鼠模型中研究rilmenidine的神经保护作用的潜力,该模型采用了链毒素诱导的DPN.
- 评估里尔梅尼丁对神经炎症,纤维化,电生理学和DPN中氧化应激的影响.
主要方法:
- 在Sprague-Dawley大鼠中使用链毒素 (STZ) 诱导糖尿病.
- 使用电肌图 (EMG) 和运动功能测试证实了DPN.
- 小鼠接受了里尔梅尼丁 (0.1或0.2毫克/公斤) 或载体四周,随后进行了坐骨神经分析.
主要成果:
- 里尔梅尼丁显著降低了坐骨神经炎症,纤维化和周围神经厚度.
- 里尔梅尼丁可以防止电生理学变化,并使神经生长因子 (NGF) 和LC-3水平正常化.
- 里尔梅尼丁通过降低甲酸和增加总抗氧化能力,提高了抗氧化能力.
结论:
- 里尔梅尼丁在老鼠模型中显示出对DPN的显著神经保护作用.
- 里尔梅尼丁的治疗效果似乎是通过调节抗氧化剂和自途径来调节的.
- 里尔梅尼丁作为治疗糖尿病外围神经病变的潜在治疗剂具有前景.
更多相关视频
05:06Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
1.7K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
592
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436